Findx
EnglishEnglish
Dansk Dansk

AIxCrypto Holdings, Inc. stock analysis FFR.US

AIxCrypto Holdings, Inc., formerly known as Qualigen Therapeutics, Inc., is a company that developed its business initially in biotechnology with a focus on oncology drug candidates. Its lead therapeutic program is QN-302, a small-molecule G-quadruplex (G4)-selective transcription inhibitor licensed from University College London. QN-302 targets G4 structures in promoter and untranslated regions of oncogenes, aiming to down-regulate cancer-related genes and inhibit proliferation of cancer cells, particularly in pancreatic, gastrointestinal, and other solid tumors. The company also maintains a preclinical Pan-RAS program, consisting of small molecules intended to block interactions of mutated RAS proteins with their effector partners.

Following a strategic rebrand in November 2025, the company shifted its corporate identity and business scope toward integrating artificial intelligence, Web3, and blockchain technologies. Its current product suite includes the BesTrade DeAI Agent and "AIxC ecosystem products," which are intended to bridge Web2 and Web3 platforms. Key elements of its crypto-focused line include the "C10" family of products: a Digital Asset Treasury, C10 Index, and a possible C10 ETF; also a C10 Stablecoin; and "Real World Asset" products featuring dual-bridge technology combining traditional financial assets with decentralized crypto assets.

Geographically, AIxCrypto is based in Carlsbad, California, and operates primarily within the United States. It maintains oncology drug research and development activities - including clinical trials - for QN-302 and its supporting pipeline from this base. In its Web3 and AI operations, the company is building a digital ecosystem with products and platforms designed for users in blockchain and crypto markets. Market segments targeted include patients and healthcare providers in oncology, as well as participants in digital asset markets, blockchain protocol users, and those engaging in AI-driven crypto or Web3 infrastructure.

Financial Services · Digital Assets · Digital Asset Treasury & Holdings · United States
Quality
Quality
Momentum
Momentum
Strength
Strength
Entry
Entry: Improving
Price has reclaimed SMA 20 and SMA 50, but it is still below SMA 200. The short- and medium-term picture has turned, while the long-term trend has not. Watch for a sustained move back above SMA 200.
Trend
Trend: Hold
The medium-term trend is intact. Price remains above SMA 20, and none of the profit-protection rules have triggered. Keep holding and let the trend work.
‹
›

Click to see warnings

Neg. values

Log in
‹
›
Years
Lower P/E (Bear)
Sign in to view
Fair Value
Sign in to view
Upper P/E (Bull)
Sign in to view
Analysts
Sign in to view
Price: Financials: Q2 FY2026 / FY2025TTM presentEstimates: UnavailableScored as: Standard companyEvidence: IncompleteDetails

Freshness

  • Price through:
  • Latest annual period: FY2025 (); filed
  • Latest interim period: Q2 FY2026 (); filed
  • TTM period: ; used by: Quality, Strength
  • No future Diluted EPS estimate is available.
  • Target price: Date unknown, Analyst count unknown

Scoring profile

Effective scoring profile: Standard company

Report a suspected classification error

Score evidence

Quality: Score calculated; Good confidence; TTM used
Business Momentum: Unavailable; Not enough evidence; TTM not used
Strength: Score calculated; Limited confidence; TTM used
  • Business Momentum score unavailable because too little of the model could be assessed. Missing: Latest surprise, Estimate revisions, Profitability, Revenue.
  • Limited confidence for Strength by model design: some checks rest on only three or four full fiscal years; diluted EPS stood in for normalized EPS.

Sources and adjustments

Remaining score inputs are provider supplied.

  • Debt to operating cash flow: derived by Findx
  • Net debt to EBITDA: derived by Findx
  • FCF margin: approved fallback

Key stock metrics

Blended P/E  :
N/A
Blended EPS  :
USD N/A
Blended EPS Yield  :
N/A
Dividend Yield :
(Trailing 12 months)
0.00%
Buyback Yield :
(Trailing 12 months)
-158.11%
Market Cap:USD 26.51 M
EUR 23.40 M

Valuation basis

Analyst price target
How this valuation works
Yearly EPS growth  :
( years incl. estimates)
N/A

P/E Values

Upper P/E:
Fair Value P/E  :
Lower P/E:
Market P/E  :
Sign in to view

EPS Estimates

:
N/A
:
N/A
:
N/A

About AIxCrypto Holdings, Inc.

Description, revenue sources, strengths and weaknesses

DESCRIPTION

AIxCrypto Holdings, Inc., formerly known as Qualigen Therapeutics, Inc., is a company that developed its business initially in biotechnology with a focus on oncology drug candidates. Its lead therapeutic program is QN-302, a small-molecule G-quadruplex (G4)-selective transcription inhibitor licensed from University College London. QN-302 targets G4 structures in promoter and untranslated regions of oncogenes, aiming to down-regulate cancer-related genes and inhibit proliferation of cancer cells, particularly in pancreatic, gastrointestinal, and other solid tumors. The company also maintains a preclinical Pan-RAS program, consisting of small molecules intended to block interactions of mutated RAS proteins with their effector partners.

Following a strategic rebrand in November 2025, the company shifted its corporate identity and business scope toward integrating artificial intelligence, Web3, and blockchain technologies. Its current product suite includes the BesTrade DeAI Agent and "AIxC ecosystem products," which are intended to bridge Web2 and Web3 platforms. Key elements of its crypto-focused line include the "C10" family of products: a Digital Asset Treasury, C10 Index, and a possible C10 ETF; also a C10 Stablecoin; and "Real World Asset" products featuring dual-bridge technology combining traditional financial assets with decentralized crypto assets.

Geographically, AIxCrypto is based in Carlsbad, California, and operates primarily within the United States. It maintains oncology drug research and development activities - including clinical trials - for QN-302 and its supporting pipeline from this base. In its Web3 and AI operations, the company is building a digital ecosystem with products and platforms designed for users in blockchain and crypto markets. Market segments targeted include patients and healthcare providers in oncology, as well as participants in digital asset markets, blockchain protocol users, and those engaging in AI-driven crypto or Web3 infrastructure.

ADDITIONAL INFO

It is very important that you understand this

Fair Value is an estimate, and you choose the basis it is built on. Do not invest based on our default without understanding how we calculate it.